Iptacopan won French access via AP1 two weeks before its EU marketing authorization even took effect.

France's Acces Precoce framework, reformed in 2021, runs two tracks: AP1 covers innovative medicines before marketing authorization, while AP2 covers medicines already authorized but not yet reimbursed. Eligibility rests on four criteria set by the Haute Autorite de Sante: a serious, rare or disabling disease, no appropriate alternative, treatment that cannot wait, and presumed innovation versus the relevant comparator. Iptacopan used this route directly: HAS granted access authorization number 2024.0128 on 2 May 2024, two weeks before Fabhalta's EU-wide marketing authorization took effect on 17 May 2024, confirming a pre-authorization, AP1 entry for PNH in France.

For a new PNH entrant, the early-access dossier, not the post-authorization Transparency Committee submission, is the first real gate. HAS's median processing time across all early-access requests was 80 days in 2023, against a three-month regulatory ceiling. Manufacturers must declare an indicative ex-tax price to CEPS at authorization, since annual rebates accrue on invoiced turnover from day one, and a retrospective rebate reconciles that price against the definitive CEPS-negotiated price once the standard appraisal closes. Iptacopan's own definitive appraisal did not land until seven months later, when the Transparency Committee rated it ASMR III on 5 December 2024, restricted to second-line use.

The early-access dossier, not the later reimbursement filing, decides who gets in first.

Five questions this report answers:

Q1 - Did our drug class already win access precoce in France, under AP1 or AP2?

Q2 - What price do we declare at authorization, and how exposed are we to the rebate?

Q3 - What must our HAS dossier contain to avoid a reimbursement gap after early access?

Q4 - What primary sources verify HAS decision numbers and dates cited in this assessment?

Q5 - How did iptacopan actually use France's Acces Precoce framework to reach PNH patients first?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#PNH #France #AccesPrecoce #MarketAccess #LaunchReadiness

Live report page:  https://axlrx.ai/pnh/france/launch-readiness/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-     hello@axlrx.ai

Web-     https://axlrx.ai/